Eshelman Innovation
Alex Abuin currently serves as the Director of R&D and Professor of the Practice at Eshelman Innovation, focusing on translating innovative therapeutic approaches into early-stage assets with strong preclinical data. Additionally, Alex is a Research Assistant Professor in the SPARK Program at the University of Vermont, where efforts are directed toward bridging biomedical research and market applications. Previous experience includes roles as Executive Director of Portfolio Management at Nurix, Inc., and Director of Strategic Industry Ventures at MD Anderson Cancer Center, emphasizing partnerships in drug development. Alex's foundational career includes positions at Lexicon Pharmaceuticals and SmithKline Beecham Pharmaceuticals, contributing to advancements in molecular genetics and drug discovery. Alex holds a Ph.D. in Molecular and Human Genetics from Baylor College of Medicine and a B.S. in Biology from the University of North Carolina at Charlotte.
This person is not in any offices
Eshelman Innovation
Eshelman Innovation is an innovation engine that turns great ideas into healthcare products and services that improve lives in North Carolina and throughout the world. Our Therapeutics Accelerator has driven novel solutions to unmet needs in oncology, neuroscience and infectious diseases. Our Venture Studio nurtures game-changing digital health startups to combat harms caused by opioid use disorder, food insecurity and more. At Eshelman Innovation, even when we encounter the most difficult healthcare problems, we don’t back away. We charge toward them.